Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Overview

The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.

Full Title of Study: “A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2008

Interventions

  • Drug: ziprasidone
    • Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase

Arms, Groups and Cohorts

  • Other: A1
    • atypical antipsychotic for the treatment of schizophrenia

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline in Weight at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • Weight value: Change = value at Week 16 or Week 16 Last Observation Carried Forward (LOCF) minus value at Baseline.

Secondary Measures

  • Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Week 16
    • Time Frame: Baseline, Week 16
    • Total cholesterol value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), and Triglycerides at Week 16
    • Time Frame: Baseline, Week 16
    • HDL, LDL, and triglyceride value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 16
    • Time Frame: Baseline, Week 16
    • HbAlc value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in Fasting Glucose at Week 16
    • Time Frame: Baseline, Week 16
    • Fasting glucose value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in Fasting Insulin at Week 16
    • Time Frame: Baseline, Week 16
    • Fasting insulin value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in Waist and Hip Circumference at Week 16
    • Time Frame: Baseline, Week 16
    • Waist and hip circumference value: Change = value at Week 16 minus value at Baseline.
  • Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score, Global Severity Score, and Global Incapacitation Score at Week 16
    • Time Frame: Baseline, Week 16
    • AIMS: a 12-item clinician administered instrument assessing observed abnormal movements in different parts of body. Ten items scored on a 5-point scale (0 = none/normal, 4 = severe) evaluate abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. Item 8 indicates severity, item 9 indicates Incapacitation. AIMS total, global severity, or global incapacitation score: Change = score at Week 16 minus score at Baseline.
  • Change From Baseline in Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score, and Positive and Negative Subscale Scores at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • PANSS measures severity of psychopathology in subjects with schizophrenia, schizoaffective disorder and other psychotic disorders. It includes 3 scales and a total of 30 items: 7 items comprise the positive scale, 7 comprise the negative scale, and 16 items measure general psychopathology. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210. PANSS total score and positive and negative scores: Change = score at Week 16 or Week 16 LOCF minus score at Baseline.
  • Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • The CGI-S is a single item, clinician-rated scale that assesses the global severity of the subject’s overall illness. The CGI-S ratings range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). CGI-S score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.
  • Observed Cases of Clinical Global Impression Improvement Scale (CGI-I) Scores at Week 16
    • Time Frame: Week 16, Week 16 LOCF
    • The CGI-I is a 7-point, single-item, clinician-rated scale that assesses global improvement in the subject’s clinical state in response to study treatment, and as compared to their status at pre-treatment baseline. Possible CGI-I scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse).
  • Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • The CDSS is a 9-item, clinician-rated scale validated for rating the severity of depressive symptoms in subjects diagnosed with schizophrenia, and independent of confounding negative and extrapyramidal symptoms. The CDSS rates the severity of depressive symptoms on a 4-point scale ranging from 0 (absent) to 3 (severe). The CDSS depression total score is obtained by adding each of the item scores. Total possible score ranges from 0 to 27. CDSS possible total score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.
  • Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Total Score and Global Rating at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • The SCoRS is a 20-question rating scale completed via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. Each question was completed using a 4-point scale (ranging from 1=none to 4=severe). Total possible score ranged from 20 to 80. At the end of the 20 questions, the interviewer completed a Global Scale of 1-10, rating subject’s overall difficulty. Higher scores on both indicated greater cognitive impairment. SCoRS total score and global rating: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.
  • Change From Baseline in Global Assessment of Function Scale (GAF) Score at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • GAF Scale measures the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale. Total possible score ranges from 0 (not enough information available to provide GAF) to 100 (Superior functioning in a wide range of activities, life’s problems never seem to get out of hand, is sought out by others because of his or her many qualities. No symptoms). The assessment was done by a trained assessor. GAF scale score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.
  • Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TQSM) Effectiveness, Side Effect, Convenience, and Global Satisfaction Subscales at Week 16
    • Time Frame: Baseline, Week 16, Week 16 LOCF
    • The TSQM is a 13-item subject-rated scale that evaluates the effectiveness, side effects and convenience of the medication over the past 2-3 weeks. Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100. TSQM Effectivenss, Side Effect, Convenience, and Global Satisfaction scores: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.

Participating in This Clinical Trial

Inclusion Criteria

  • Males or females, between 18 and 55 years of age, at the time of consent. – Subjects must have a primary diagnosis of schizophrenia, any subtype (code 295.xx), or schizoaffective disorder as defined in DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition) – Subjects must have normal vital signs, physical examination, ECG, and laboratory findings except for minor deviations determined and documented to be clinically insignificant by the investigator or a sub-investigator who is a medical doctor. Exclusion Criteria:

  • Subjects who are unable to provide informed consent – Subjects who meet criteria for a DSM-IV-TR Axis I (Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition) diagnosis other than schizophrenia or schizoaffective disorder, including psychoactive substance abuse or dependence within one year of study entry – Females who are pregnant, breast feeding, or lactating at screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.